COMPUTED DESCRIPTORS
| Molecular Weight | 276.4 g/mol |
|---|---|
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 276.17254462 g/mol |
| Monoisotopic Mass | 276.17254462 g/mol |
| Topological Polar Surface Area | 43.4 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 494 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Anti-claudin 18.2 Monoclonal Antibody M108 is a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody M108 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. The binding induces antibody-dependent cellular cytotoxicity (ADCC) and may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.